AIM ImmunoTech Inc. (AIM) Form 8-K — Aug 6, 2026
AIM ImmunoTech entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026 under which Sterling will manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U, the polymer precursors to Ampligen, at its Dudley, UK facility. The estimated cost is approximately $1.5 million, payable over 12 months; the attached proposal shows an estimated total of $1,446,200 covering process development, non-GMP demonstration batches, analytical method validation, and one cGMP batch each of PolyI and Poly C12U.
Key figures
- Deal Value Usd
- approximately $1.5 million
- Cgmp Batches
- one cGMP batch each of PolyI and Poly C12U
- Estimated Total Usd
- 1446200
- Payment Period Months
- 12
- Gbp Usd Conversion Rate
- 1.33
- Non Gmp Demo Batch Weeks
- 3 calendar weeks per polymer
- Process Development Window
- 12 calendar weeks
- Director Nomination Deadline
- 2026-09-17
- Universal Proxy Notice Deadline
- 2026-10-19
Price after filing
Close on the filing date to close N calendar days later (from $0.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.